<DOC>
	<DOCNO>NCT02272946</DOCNO>
	<brief_summary>The purpose study evaluate effect IL-1β inhibition safety , measure systemic vascular inflammation endothelial function ( indicator cardiovascular risk ) treat suppressed HIV infect individual This study assess safety effect canakinumab endothelial function ( assessed flow-mediated vasodilation [ FMD ] brachial artery ) , vascular inflammation ( assessed FDG-PET/CT scanning ) , key inflammatory marker cardiovascular disease ( CVD ) risk ( high-sensitivity C-reactive protein [ hsCRP ] ) , interleukin-6 ( IL-6 ) , soluble CD163 ( sCD163 ) , D-dimer , T-cell monocyte activation blood , size HIV reservoir . 20 individual receive single dose 150mg canakinumab follow-up 18 week .</brief_summary>
	<brief_title>Effect IL -- 1β Inhibition Inflammation Cardiovascular Risk</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . HIV infection , 2 . Age ≥ 40 year 3 . On continuous ART least 12 month change regimen 12 week prior study entry 4 . CD4+ T cell count ≥ 400 cells/mm3 5 . HIV RNA level standard limit quantification 52 week prior entry 6 . High risk CAD define either document CVD ( include prior MI ) diabetes mellitus 1 CVD risk factor ( current smoking , hypertension , dyslipidemia , hsCRP≥2mg/L . ) 7 . Individuals stable dos lipid lower therapy , diabetes medication ( include insulin ) and/or antihypertensive medication allow study . 8 . Appropriate documentation medical record prior receipt pneumococcal vaccination 1 . Women childbearing potential pregnant/nursing woman 2 . CABG surgery past 3 year 3 . Class IV heart failure 4 . Uncontrolled HTN diabetes 5 . History tuberculosis latent TB treat 6 . Nephrotic syndrome eGFR &lt; 30 ml/min/1.73m2 7 . Active hepatic disease active/chronic hepatitis B C 8 . Any prior malignancy include KS 9 . Serious illness require hospitalization active infection require antibiotic within 90 day 10 . Requirement live active vaccination 3 month prior , , 3 month study 11 . Concurrent immune modulate therapy 12 . Requirement insulin 13 . History multiple imaging study associate radiation exposure 14 . Neutropenia define ANC &lt; 1500/mm 15 . Triglycerides &gt; 400 mg/dL 16 . History hypersensitivity study drug 17 . History EBVrelated lymphoproliferative disorder 18 . Active untreated latent TB infection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>